Avian influenza A/H5N1: Collected risk assessments, technical guidance to public health authorities and advice to the general public
The document determines the risk to human health in Europe from highly pathogenic avian influenza viruses in birds and animals and identifies areas requiring additional scientific and public health work both as single pieces of work and for risk monitoring by ECDC and its partners.
Risk assessment: The Public Health Risk from Highly Pathogenic Avian Influenza Viruses Emerging in Europe with Specific Reference to type A/H5N1 Version June 1st 2006
The objective of this revised document is to further determine the risk to human health in Europe from highly pathogenic avian influenza viruses in birds and animals. Specifically the additional risk that arises from the recent emergence and extension of A/H5N1 viruses into the European Union and elsewhere in the world, and the changed biology of the viruses among wild and domestic birds.
Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.